Revolade 25mg (Eltrombopag)

DESCRIPTION

Eltrombopag is sold under the brand name Revolade and it is a man-made form of a protein that increases production of platelets (blood-clotting cells) in your body.
Revolade 25mg can reduces the risk of bleeding by increasing platelets in your blood.
Revolade 25mg which is used asprescription drug under the guidance of the medical practioners

INDICATION

Revolade 25mg isan anticancer medication which is;

Indicated for the treatment of patients having Severe aplastic Anemia

• First line treatment of severe aplastic Anemia

• Treatment of refractory severe aplastic Anemia

Indicated for the treatment to stimulate the growth and development of platelets in the bone marrow

Primarily indicated for the treatment of patients having reduced platelet counts due to chronic hepatitis C virus infection

MECHANISM OF ACTION

Eltrombopag consist of class of drugs known as thrombopoietin (TPO) receptor agonists. A class of drugs is a group of medications which work in a same way.

Eltrombopag mechanism by raising cells in your bone marrow and causes these cells to make more platelets. This effect reduces your risk of bleeding.

PHARMACOKINETICS

 Absorption:
High plasma concentration is 2-6 hours
Distribution:
Maximum human plasma protein bounding is >99% and in blood plasma level is 50% to 79%
Metabolism:
generally metabolised via cleavage, oxidation and conjugation with glucuronic acid.
Elimination:
Revolade 25mg eliminated mainly via feces 59%, along with 31% via renally excreted
Revolade 25mg Half-life for healthy patients is 21-23 hours and idiopathic thrombocytopenic purpura is 26-35 hours.

DOSAGE MANAGEMENT

• The usual dose for Chronic Hepatitis C-associated Thrombocytopenia is 25 mg PO qDay. Dose is managed in 25 mg accretion q2weeks PRN to attain target Plt needed to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day
• Severe Aplastic Anemia :
1.First-line therapy :
When combination with standard immunosuppressive treatment, for patients with serious aplastic Anemia (SAA)
The usual dose for severe Aplastic Anemia: 150 mg PO qDay for 6 months
Avoid taking of more than starting dose; total duration is 6 months
2.Refractory SAA :

In this condition the drug given who fail to respond enough to at least 1 before immunosuppressive therapy
The usual dose for Refractory SAA: 50 mg PO qDay
• The recommended dose for Chronic Immune Thrombocytopenia is 50 mg PO qDay Adjust dose to manage and control platelet count (Plt) >50 x 10^9/L to reduce the risk of bleeding; not to exceed 75 mg/day

PRECAUTION

• The drug Revolade 25mg may have high risk of severe and probably life-threatening hepatotoxicity; monitor liver function before and during treatment
• While receiving the drug, if patient with hepatic impairment (Child-Pugh Class A, B, C) initiates therapy for first- line treatment of severe aplastic Anemia, reduce initial dose
• When treatment, If the patients have cataracts, do not use the drug due to the Revolade 25mg effects cataracts and make the condition worse.
• Avoid the Revolade 25mg while the patients have myelodysplastic syndrome (MDS), will increases the risk of death.
• While on treatment with drug Revolade then Portal vein thrombosis reported in patients with chronic liver disease.

SIDE EFFECTS

Common side effects of Revolade 50mg  :
• Headache
• Cough
• Loss of appetite
• Flu
• Reduced red blood cells
• Diarrhoea
• Nausea
• Fever
• Weakness
Serious side effects of Revolade 50mg  :
• Swelling of legs
• Abdomen swelling
• Confusion
• Chest pain
• Dyspnea
• Cloudy vision
• Urine in dark colour
• Yellowing of your skin
• Sensitivity to light
• Seeing circles around lights

DRUG INTERACTION

When Revolade 25mg  interacts with Cholesterol-reducing drugs like atorvastatin, fluvastatin, rosuvastatin, pravastatin, and simvastatin, pitavastatin combination with Revolade 25mg . Have high side effects can contains muscle pain. The doctor may decrease the dosage of your cholesterol drugs.

When Revolade 25mg  interactionwithezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan will increase the side effects. Hence thedoctor may decrease your dosage of these drugs if necessary.

Antacids, vitamins, or supplements which involves Ca, Al, Fe, Se, Zn, or Mg concomitant use with Revolade 25mg . To stop interactions, then take Revolade two hours before or four hours after administrating any of these products.

PREGNANCY

Pregnancy category is C
Safety of drug during pregnancy is not established.

LACTATION

During breast feeding, avoid using of drug Revolade 25mg

STORAGE

Store at room temperature 20°C and 25°C.

MISSED DOSE

If the missed dose occurs, patients must consult with medical practitioner and follow the instructions given by them.

Therefore, missed dose should be avoid and follow the regular dosing schedule.